Advertisement

Advertisement
William A. Wood, MD, MPH, on the New ASH Research Collaborative Data Hub COVID-19 Registry for Hematologic Malignancy

William A. Wood, MD, MPH, on the New ASH Research Collaborative Data Hub COVID-19 Registry for Hematologic Malignancy

It’s T Time for Peripheral T-Cell Lymphoma, a Much-Neglected Disease

It’s T Time for Peripheral T-Cell Lymphoma, a Much-Neglected Disease

The lymphomas are an incredibly complex assemblage of neoplastic diseases. They are not one disease, and, at least based on the World Health Organization...

Vitamin D and Lymphoma: An Apparent Benefit, but Further Study Required

Vitamin D and Lymphoma: An Apparent Benefit, but Further Study Required

Vitamin D is a steroid-like hormone involved primarily in human calcium homeostasis. Obtained through sun exposure as well as food and dietary supplements...

FDA Approves Ibrutinib/Rituximab for CLL/SLL

On April 21, the U.S. Food and Drug Administration (FDA) expanded the indication of ibrutinib (Imbruvica) to include its combination with rituximab for the initial treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

KTE-X19 for Relapsed or Refractory Mantle Cell Lymphoma: ZUMA-2 Trial

In a phase II trial reported in The New England Journal of Medicine, Michael Wang, MD, and colleagues found that the anti-CD19 chimeric antigen receptor T-cell therapy KTE-X19 produced a high response rate in patients with relapsed or refractory mantle cell lymphoma who had received previous BTK inhibitor therapy.

Nivolumab for Children and Young Adults With Relapsed or Refractory Solid Tumors or Lymphoma

In a phase I/II study reported in The Lancet Oncology, Davis et al identified the phase II dosage of nivolumab monotherapy in children and young adults with relapsed or refractory solid tumors or lymphoma. Objective responses were observed in patients with lymphoma, but not in those with solid tumors.

Advertisement


Advertisement